Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression.
OBJECTIVE
It is known that major histocompatibility complex class II protein HLA-DR is highly expressed in B-cell lymphomas and in a variety of autoimmune and inflammatory diseases. Therefore, a radiolabelled fully humanized IgG4 monoclonal antibody (mAb) can provide useful prognostic and diagnostic information. Aims of the present study were to radiolabel an anti-HLA-DR mAb with technetium-99m and to evaluate its binding specificity, tissue distribution and targeting potential.


METHODS
For labelling, we compared a direct method, after 2-mercaptoethanol (2-ME) reduction of disulphide bonds, with a two-step labelling method, using a heterobifunctional succinimidyl-6-hydrazinonicotinate hydrochloride chelator. Several in vitro quality controls and in vivo experiments in mice were performed.


RESULTS
We obtained highest labelling efficiency (LE, >98%) and specific activity (SA; 5,550 MBq/mg) via the direct method. In vitro quality control showed good stability, structural integrity and retention of the binding properties of the labelled mAb. The biodistribution in mice showed high and persistent uptake in spleen and suggests kidney and liver-mediated clearance pathways. In tumour targeting experiments, we observed high uptake in HLA-DR-positive xenografts compared to controls. In vivo binding was proportional to the number of injected cells. In the in vivo blocking assay, uptake of radiolabelled mAb was significantly decreased in mice pre-injected with 100-fold molar excess of unlabelled mAb.


CONCLUSIONS
We efficiently labelled a humanized anti-HLA-DR mAb with (99m)Tc using a direct labelling method. Radiolabelled mAb binds to human HLA-DR antigens and therefore warrants further evaluation as a prognostic and diagnostic tool for patients with lymphoma or autoimmune diseases.
Malviya
Gaurav
G
Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. gaurav.malviya@yahoo.com
de Vries
E F J
EF
Dierckx
Rudi A
RA
Signore
Alberto
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D013667:Technetium / Q000737:chemistry*; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D000949:Histocompatibility Antigens Class II; D013667:Technetium
J Mol Recognit. 2008 May-Jun;21(3):179-83
18438972
Semin Cancer Biol. 1991 Feb;2(1):47-54
1912518
Nat Med. 2002 Aug;8(8):801-7
12101408
Blood. 1990 Jun 15;75(12):2375-87
1693529
Circulation. 1992 Feb;85(2):738-46
1735166
Anticancer Res. 2003 May-Jun;23(3A):2139-42
12894588
Transplantation. 1988 Apr;45(4):677-82
3258681
J Nucl Med. 1990 May;31(5):692-7
2341907
Cancer Res. 2007 Apr 1;67(7):3269-75
17409435
Transpl Int. 1993;6(5):263-9
8216702
Q J Nucl Med Mol Imaging. 2007 Dec;51(4):334-42
17464276
Jpn J Cancer Res. 1989 Dec;80(12):1149-52
2516841
J Clin Invest. 2001 Apr;107(7):795-6
11285296
Int J Cancer Suppl. 1988;3:96-101
3209308
Appl Radiat Isot. 2006 Jan;64(1):32-7
16055339
Cancer Res. 1987 Feb 1;47(3):830-40
3542194
Q J Nucl Med Mol Imaging. 2007 Jun;51(2):204-10
17420719
J Exp Med. 1992 Aug 1;176(2):629-34
1500864
Immunol Rev. 1986 Oct;93:103-24
3491034
J Immunol Methods. 1984 Aug 3;72(1):77-89
6086763
Transplantation. 1989 Sep;48(3):506-10
2675409
Cancer Res. 2006 Feb 1;66(3):1799-808
16452241
Curr Opin Mol Ther. 2008 Feb;10(1):68-74
18228184
Appl Radiat Isot. 2006 Aug;64(8):901-5
16618544
Leuk Lymphoma. 2007 Mar;48(3):542-6
17454596
Int J Cancer. 1998 Jul 17;77(2):251-6
9650561
Immunogenetics. 1996;43(3):152-5
8550099
Cancer Immunol Immunother. 1994 Jun;38(6):358-64
8205556